Can Idenix be duplicated?

Capital Rationing

Venture firms unable to exit their portfolio companies via an IPO are looking for novel ways to monetize their investments. Witness last week's deal in which Novartis AG obtained a 51% stake in Idenix Pharmaceuticals Inc. by paying $255 million in cash to existing Idenix shareholders, who could take in another $357 million if Idenix meets its milestones...